| Oscar Insurance Guidelines | Oscar Clinical Guideline: Direct Acting Antiviral Agents for Hepatitis C | 2025-12-01 |
| Oscar Insurance Guidelines | Oscar Clinical Guideline: azelaic acid 15% gel | 2025-12-01 |
| UHC Medicare Advantage | Orthopedic Procedures, Devices, and Products – Medicare Advantage Medical Policy | 2025-12-01 |
| UHC Medicare Advantage | Prostate Services and Procedures and Impotence Treatment – Medicare Advantage Medical Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Benlysta® (Belimumab) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Evenity® (Romosozumab-Aqqg) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Ophthalmologic Complement Inhibitors – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Review at Launch for New to Market Medications – Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC UMR Medical and Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Commercial Medical Benefit Drug Policy | 2025-12-01 |